Loading
India's first home-made HPV vaccine, protecting against the two virus types that cause most cervical cancers and the two that cause genital warts, at a price meant for a national programme.
CERVAVAC is a quadrivalent HPV vaccine (types 6, 11, 16 and 18) developed by the Serum Institute of India with Department of Biotechnology support and produced in Hansenula polymorpha yeast. It is indicated for girls and women aged 9 to 26 against cervical, vulvar, vaginal and anal cancers and genital warts, and for boys and men aged 9 to 26 against anal cancer and genital warts; the schedule is two doses at 0 and 6 months for ages 9 to 14 and three doses (0, 2 and 6 months) for ages 15 to 26. It received Indian market authorisation in 2022 and was introduced in 2023, and published comparisons report immunogenicity non-inferior to established vaccines.
Its importance is supply and price: India records about 127,500 cervical cancer cases and 79,900 deaths a year (GLOBOCAN 2022), and vaccination depended on two imported products. A domestic vaccine, together with the IARC India evidence that a single dose protects as well as two or three, is what makes a national programme for girls aged 9 to 14 affordable; its proposed inclusion in the Universal Immunisation Programme is described in the 2026 literature as a milestone still being rolled out.
Recombinant L1 capsid proteins of HPV 6, 11, 16 and 18 self-assemble into virus-like particles that induce neutralising antibodies preventing persistent infection.
1.L1 protein particles mimic the virus shell without DNA
Source: www.seruminstitute.com/product_ind_cervavac.php. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| IN | 2022 | Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26 · Market authorisation from the DCGI in 2022; introduced 2023 |
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| IN | Planned for the Universal Immunisation Programme; state programmes and private market meanwhile | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One dose protects. WHO endorsed one- or two-dose schedules in 2022, halving the cost and the logistics of vaccinating girls, which is decisive for India (about 127,500 cervical cancers a year) and for the global elimination target. It also removed the main barrier to India's national programme with its home-made vaccine.
Query for this drug: (TITLE:"CERVAVAC" OR ABSTRACT:"CERVAVAC" OR TITLE:"quadrivalent HPV vaccine, India" OR ABSTRACT:"quadrivalent HPV vaccine, India" OR TITLE:"qHPV vaccine Serum Institute" OR ABSTRACT:"qHPV vaccine Serum Institute" OR TITLE:"Cervavac" OR ABSTRACT:"Cervavac") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CERVAVAC (quadrivalent HPV vaccine, India), not a curated reading list.
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), Nonavalent HPV vaccine.
Shares International Agency for Research on Cancer (IARC / WHO), Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares International Agency for Research on Cancer (IARC / WHO), Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care.
Shares International Agency for Research on Cancer (IARC / WHO), Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, HPV & HBV vaccination, Prevention we already have is not deployed, Most of the world has almost no cancer care.